|
|
| Line 1: |
Line 1: |
| {{drugbox
| |
| | IUPAC_name = (5α, 17β)-''N''-{2,5 bis(trifluoromethyl) phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide
| |
| | image = Dutasteride.png
| |
| | width = 217
| |
| | CAS_number = 164656-23-9
| |
| | ATC_prefix = G04
| |
| | ATC_suffix = CB02
| |
| | ATC_supplemental =
| |
| | PubChem = 152945
| |
| | DrugBank = APRD00385
| |
| | C=27 | H=30 | F=6 | N=2 | O=2
| |
| | molecular_weight = 528.53 g/mol
| |
| | bioavailability = 60%
| |
| | protein_bound = 99%
| |
| | metabolism = [[Liver|Hepatic]] ([[CYP3A4]]-mediated)
| |
| | elimination_half-life = 5 weeks
| |
| | excretion = Fecal
| |
| | pregnancy_US = X
| |
| | pregnancy_category = '''Not to be handled by pregnant women'''
| |
| | legal_UK = POM
| |
| | legal_US = Rx-only
| |
| | routes_of_administration = Oral
| |
| }}
| |
| {{SI}}
| |
|
| |
|
|
| |
| ==Overview==
| |
| '''Dutasteride''' (marketed as '''Avodart''', '''Avidart''', '''Avolve''', '''Duagen''', '''Dutas''', '''Dutagen''', '''Duprost''') is a [[5-alpha-reductase inhibitor]], a [[medication|drug]] which inhibits the conversion of [[testosterone]] into [[dihydrotestosterone]] (DHT). It is used to treat conditions caused by DHT, such as [[benign prostatic hyperplasia]] (BPH).
| |
|
| |
| ===Classification and Method of Action===
| |
|
| |
| Dutasteride belongs to a class of drugs called 5-alpha-reductase inhibitors, which block the action of the [[5-alpha-reductase]] [[enzyme]]s that convert testosterone into dihydrotestosterone (DHT). [[Finasteride]] also belongs to this group. Dutasteride inhibits both isoforms of 5-alpha reductase, while finasteride inhibits only one. But a clinical study done by GlaxoSmithKline, the EPICS trial, did not find dutasteride to be more effective than finasteride in treating BPH.
| |
|
| |
| ===Uses===
| |
|
| |
| While dutasteride is officially approved to treat enlargement of the [[prostate|prostate gland]]. Clinical trials for dutasteride as a hair loss drug were undertaken, but called off in late 2002. The reason the trials were called off is not publicly known. Industry sources speculate that Avodart would have been seen as too similar to Propecia to have proved profitable as a hair loss treatment.
| |
|
| |
| In December 2006, Avodart manufacturer [[GlaxoSmithKline]] embarked on a new Phase III, six month study in Korea to test the safety, tolerability and effectiveness of a once-daily dose of dutasteride (0.5mg) for the treatment of [[male pattern baldness]] in the vertex region of the scalp (types IIIv, IV and V on the [[Hamilton-Norwood scale]]).<ref>{{ClinicalTrialsGov|NCT00441116}}</ref> The future impact that this study will have on the [[FDA]]'s approval or disapproval of Avodart for the treatment of [[male pattern baldness]] in the [[United States]] is yet to be determined.
| |
|
| |
| ==See also==
| |
| *[[baldness treatments]]
| |
| *[[finasteride]]
| |
|
| |
| ==External links==
| |
| *[http://www.sciencedaily.com/releases/2007/06/070611113313.htm Effectiveness of Dutasteride as a treatment for Male Pattern Baldness, as reported by Science Daily.]
| |
| *[http://www.avodart.com Official site]
| |
| *http://www.hairlosshelp.com/html/Dutasteride_hair_loss_trials.cfm
| |
| *[http://www.regrownow.com/5.html Information on suspended trials for Avodart as a hair loss treatment] ''Accessed 02/09/2006''
| |
|
| |
| ==References==
| |
| <references/>
| |
|
| |
| {{Urologicals}}
| |
|
| |
|
| |
| [[Category:5-alpha-reductase inhibitors]]
| |
| [[Category:Hair loss]]
| |
|
| |
| [[de:Dutasterid]]
| |
| [[fi:Dutasteridi]]
| |
|
| |
| {{WH}}
| |
| {{WS}}
| |